AAAAAA
Results:
1-16
|
Results: 16
Authors:
HAYCOX A
BUTTERWORTH M
WALLEY T
BARTON S
Citation: A. Haycox et al., DEVELOPMENT OF AN ECONOMIC-MODEL FOR THE MANAGEMENT OF UPPER GASTROINTESTINAL-DISEASE IN PRIMARY-CARE - PRELIMINARY FINDINGS, PharmacoEconomics, 14, 1998, pp. 11-23
Authors:
HAYCOX A
DUBOIS D
BUTTERWORTH M
Citation: A. Haycox et al., CUSTOMIZING AN INTERNATIONAL DISEASE MANAGEMENT MODEL TO THE NEEDS OFINDIVIDUAL COUNTRIES - APPLICATION TO UPPER GASTROINTESTINAL-DISEASE, PharmacoEconomics, 14, 1998, pp. 39-56
Authors:
WHITAKER M
DUGGAN A
HAYCOX A
TOSETTI C
COOKSON R
MAYNARD A
Citation: M. Whitaker et al., QUESTIONS AND ANSWERS, PharmacoEconomics, 14, 1998, pp. 73-75
Authors:
HAYCOX A
LOMBARD M
NEOPTOLEMOS J
WALLEY T
Citation: A. Haycox et al., REVIEW ARTICLE - CURRENT PRACTICE AND FUTURE PERSPECTIVES IN DETECTION AND DIAGNOSIS OF PANCREATIC-CANCER, Alimentary pharmacology & therapeutics, 12(10), 1998, pp. 937-948
Authors:
HAYCOX A
LOMBARD M
NEOPTOLEMOS J
WALLEY T
Citation: A. Haycox et al., REVIEW ARTICLE - CURRENT TREATMENT AND OPTIMAL PATIENT-MANAGEMENT IN PANCREATIC-CANCER, Alimentary pharmacology & therapeutics, 12(10), 1998, pp. 949-964
Authors:
HAYCOX A
Citation: A. Haycox, COST-EFFECTIVENESS OF TREATMENT FOR GASTROESOPHAGEAL REFLUX DISEASE -REPLY, Gut, 43(5), 1998, pp. 729-730
Authors:
EGGLESTON A
WIGERINCK A
HUIJGHEBAERT S
DUBOIS D
HAYCOX A
Citation: A. Eggleston et al., COST-EFFECTIVENESS OF TREATMENT FOR GASTROESOPHAGEAL REFLUX DISEASE IN CLINICAL-PRACTICE - A CLINICAL DATABASE ANALYSIS, Gut, 42(1), 1998, pp. 13-16
Authors:
HUMPHREY KM
CORK MJ
HAYCOX A
Citation: Km. Humphrey et al., A RETROSPECTIVE COST-EFFECTIVENESS ANALYSIS OF THE TREATMENT OF ONYCHOMYCOSIS IN GENERAL-PRACTICE, British journal of dermatology, 139(4), 1998, pp. 660-664
Authors:
WALLEY T
HAYCOX A
BARTON S
Citation: T. Walley et al., DRUG RATIONING IN THE UK NATIONAL-HEALTH-SERVICE - CURRENT STATUS ANDFUTURE-PROSPECTS, PharmacoEconomics, 12(3), 1997, pp. 339-350
Authors:
HAYCOX A
DRUMMOND M
WALLEY T
Citation: A. Haycox et al., PHARMACOECONOMICS - INTEGRATING ECONOMIC-EVALUATION INTO CLINICAL-TRIALS, British journal of clinical pharmacology, 43(6), 1997, pp. 559-562
Authors:
HAYCOX A
WALLEY T
Citation: A. Haycox et T. Walley, PHARMACOECONOMICS - EVALUATING THE EVALUATORS, British journal of clinical pharmacology, 43(5), 1997, pp. 451-456
Authors:
WALLEY T
HAYCOX A
Citation: T. Walley et A. Haycox, PHARMACOECONOMICS - BASIC CONCEPTS AND TERMINOLOGY, British journal of clinical pharmacology, 43(4), 1997, pp. 343-348
Authors:
EGGLESTON A
WIGERINCK A
HAYCOX A
Citation: A. Eggleston et al., COST OF GORD-MEDICATION IN CLINICAL-PRACTICE IN PATIENTS WITH A FIRSTDIAGNOSIS OF GORD BASED ON PRESCRIPTION-DATA ANALYSIS (MEDIPLUS UK), Gastroenterology, 112(4), 1997, pp. 13-13
Authors:
EGGLESTON A
WIGERINCK A
HAYCOX A
Citation: A. Eggleston et al., OUTCOME RESEARCH IN GORD - RETROSPECTIVE ANALYSIS OF PRESCRIPTION DATA (MEDIPLUS(R) UK) ON CISAPRIDE (CIS), RANITIDINE (RAN) AND OMEPRAZOLE(OME), Gastroenterology, 112(4), 1997, pp. 13-13
Authors:
HAYCOX A
BARTON S
WALLEY T
Citation: A. Haycox et al., COST-EFFECTIVENESS OF LOWERING CHOLESTEROL - STUDY DID NOT TAKE ACCOUNT OF CONFOUNDERS, BMJ. British medical journal, 313(7065), 1996, pp. 1142-1143
Authors:
HAYCOX A
Citation: A. Haycox, A METHODOLOGY FOR ESTIMATING THE COSTS AND BENEFITS OF HEALTH PROMOTION, Health promotion international, 9(1), 1994, pp. 5-11
Risultati:
1-16
|